News | Artificial Intelligence | November 25, 2022

Site becomes second in the world to offer first-of-a-kind technology for screening women with dense breasts

Site becomes second in the world to offer first-of-a-kind technology for screening women with dense breasts

November 25, 2022 — Delphinus Medical Technologies has announced the installation of its SoftVue 3D Whole Breast Ultrasound Tomography System (SoftVue) at East Alabama Medical Center, making the site the second in the world to purchase and offer patients the FDA-approved technology for screening women with dense breast tissue. 

Dense breast tissue is common, affecting 40 percent of women and making them four times more likely to develop breast cancer. Compounding the increased risk, dense breast tissue typically appears white on a mammogram, as does cancer, making clinicians miss roughly half of new cancer cases. 

When paired with a screening mammogram, SoftVue has been shown to identify up to 20 percent more cancers while also reducing false positives and decreasing unnecessary call-backs and biopsies. 

“We developed SoftVue to fit a very real unmet need for patients with dense breasts who need better screening modalities that can find more cancers,” Mark J. Forchette, president and CEO, Delphinus Medical Technologies, Inc. “As an Auburn University graduate, I am excited that the East Alabama community is at the forefront of dense breast screening innovation and has an opportunity to lead a global transformation in imaging that will save hundreds of thousands of lives.” 

The FDA approval of SoftVue, used as an adjunct to mammography, allows women with dense breast tissue to have both cancer screening tests during a single appointment. Taking approximately eight to 10 minutes, a SoftVue exam uses warm water and ultrasound technology to create a 3D image of the whole breast to detect the presence of cancer in its earliest stages — including masses in dense breast tissue often missed by mammography alone — while avoiding radiation exposure and compression, allowing the radiologist to make a more accurate diagnosis. 

“We are committed to providing our patients with superior screening technology. SoftVue will further strengthen our fight against breast cancer, which accounts for one in three new cancer diagnoses in women each year,” said Laura Grill, East Alabama Health president and CEO. “The key to breast cancer survival is early detection, and this new screening device will be lifesaving for so many women in our community.” 

For more information: www.delphinusmt.com 

Find more RSNA22 coverage here 


Related Content

News | Cardiac Imaging

May 21, 2026 — A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s ...

Time May 22, 2026
arrow
News | X-Ray

May 21, 2026 — RADIN Health and AZmed have announced the expansion of their strategic partnership and enhance radiology ...

Time May 22, 2026
arrow
News | Digital Pathology

May 7, 2026 — Roche has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital ...

Time May 21, 2026
arrow
News | Ultrasound Imaging

May 20, 2026 — The Focused Ultrasound Foundation has announced the launch of the International Focused Ultrasound ...

Time May 21, 2026
arrow
News | Computed Tomography (CT)

May 12, 2026 – Bracco Imaging S.p.A. has purchased a mobile photon-counting CT scanner from MARS Bioimaging to support ...

Time May 20, 2026
arrow
Feature | Enterprise Imaging | Kyle Hardner

For radiology departments, the imbalance between surging imaging volume and a shortage of trained radiologists is taking ...

Time May 20, 2026
arrow
News | Radiology Imaging

May 18, 2026 — DICO, a company specializing in the creation of distributed diagnostic infrastructure for radiology, has ...

Time May 19, 2026
arrow
News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
Subscribe Now